N-JARID2

N-JARID2 is a peptide-based therapeutic candidate derived from the N-terminal domain of the JARID2 protein. JARID2 is a critical regulatory component of the Polycomb Repressive Complex 2 (PRC2), which mediates gene silencing through the trimethylation of histone H3 at lysine 27 (H3K27me3). In certain malignancies, such as alveolar rhabdomyosarcoma (aRMS), JARID2 is overexpressed and acts as a key driver of the oncogenic program by recruiting PRC2 to specific genomic loci. N-JARID2 functions as a dominant-negative inhibitor or decoy that interferes with the assembly of the PRC2 core complex or its recruitment to target genes. By disrupting the JARID2-PRC2 axis, N-JARID2 can reverse the epigenetic silencing of tumor-suppressive genes, leading to inhibited cell proliferation and induced differentiation in cancer cells. It is primarily investigated in preclinical research for the treatment of PRC2-dependent pediatric cancers.

Other names

JARID2 N-terminal peptideJARID-2 N-terminal peptideJARID 2 N-terminal peptideN-terminal JARID2 fragment